Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

NCT01889797 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT01889797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01889797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2013
Completion date
August 31, 2016
Enrollment
32 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non-hodgkin's lymphoma